Intercell AG: Changes to the Supervisory Board

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

Wien (euro adhoc) - Vienna (Austria), December 15, 2006 - Intercell
AG (VSE, "ICLL") announced today the following realignment in its
Supervisory Board:

Hans Küpper, who represented the private equity firm Global Life
Science Ventures on Intercell’s Supervisory Board, resigns from his
position resigned with effect of today.

The company would like to thank Hans Küpper for his good cooperation
and long-term commitment to the company.

With this resignation, all venture capital firms have now left
Intercell’s Supervisory Board. The Supervisory Board now includes the
following members: Michel Gréco (Chairman), Ernst-Günter Afting
(Vice-chairman), Staph Bakali, David Ebsworth, James Sulat and Hans
Wigzell.

About Intercell AG

Intercell AG is a biotechnology company focused on the research,
development, manufacturing and future commercialization of innovative
vaccines for the prevention and treatment of infectious diseases, for
which there exists a substantial unaddressed medical need. Intercell
develops antigens and immunizers (adjuvants), which are derived from
its proprietary technology platforms and has in-house GMP
manufacturing capability. Intercell has strategic partnerships with a
number of global pharmaceutical companies, including Novartis, Wyeth,
Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and
the Statens Serum Institut.

Intercell has a broad development pipeline with a vaccine product
candidate for Japanese Encephalitis in Phase III clinical trials, a
vaccine product candidate for Hepatitis C in Phase II, partnered
vaccine candidates for Tuberculosis and S. aureus, which are in Phase
I, and more than five other product candidates focused on infectious
diseases in pre-clinical development. Intercell is listed on the
Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

end of announcement euro adhoc 15.12.2006 08:14:28
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market